DDInter1627 DDInter648
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN7A
SCN7A {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Rufinamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Rufinamide {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Rufinamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Entrectinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Entrectinib
Rufinamide {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Rufinamide {u} (Compound) causes {v} (Side Effect) Atrioventricular block first degree
Atrioventricular block first degree {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Entrectinib
Rufinamide (Compound) binds SCN7A (Gene) and SCN7A (Gene) is bound by Procainamide (Compound) and Procainamide may lead to a major life threatening interaction when taken with Entrectinib
Rufinamide (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Rufinamide (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Rufinamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Rufinamide (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Rufinamide (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Entrectinib
Rufinamide (Compound) causes Atrioventricular block first degree (Side Effect) and Atrioventricular block first degree (Side Effect) is caused by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Entrectinib